Altre lingue PMV Pharmaceuticals, Inc.

Azioni

PMVP

US69353Y1038

Tempo reale stimato Cboe BZX Altri mercati azionari 18:26:12 11/07/2024			Variaz. 5gg	Var. 1 gen.
1,53 ^USD	+3,38%		+1,67%	-50,81%

29/05	PMV Pharmaceuticals, Foundation Medicine svilupperanno un diagnostico complementare per Rezatapopt	MT
29/05	Foundation Medicine e PMV Pharma annunciano una collaborazione per sviluppare un diagnostico complementare per Rezatapopt	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell Small Cap Completeness Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2000 Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 3000E Value Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 3000E Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 3000 Value Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2500 Value Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell Small Cap Comp Value Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2000 Value Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2000 Dynamic Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2500 Index	01/07
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 3000 Index	01/07
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June	30/05
PMV Pharmaceuticals, Foundation Medicine to Develop Companion Diagnostic for Rezatapopt	29/05
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	29/05
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	29/05
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt	29/05
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights	09/05
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	27/03
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	27/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue PMV Pharmaceuticals, Inc.

Azioni

PMVP

US69353Y1038

Altre lingue

Filtri